Overview

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KRP-A218 in Healthy Subjects

Status:
Recruiting
Trial end date:
2022-03-23
Target enrollment:
Participant gender:
Summary
This first-in-human study has three parts. In Parts A and B, the safety, tolerability, and pharmacokinetics (PK) will be evaluated following administration of single and multiple doses of KRP-A218, including food-effect. In Part C, the drug-drug interaction (DDI) with itraconazole will be evaluated.
Phase:
Phase 1
Details
Lead Sponsor:
Kyorin Pharmaceutical Co.,Ltd
Treatments:
Itraconazole